OTC Analgesics Series: Podcast #1 - OTC Analgesic Mechanisms of Action
Release Date: December 15, 2018
Expiration Date: December 15, 2019
This educational activity is provided by Dannemiller
Supported by an educational grant from Pfizer Inc
Physicians, Nurse Practitioners, Registered Nurses, and Pharmacists
Upon completion of this activity, the participant should be able to:
- Review the different mechanisms of action for OTC analgesics.
Statement of Need
Pain is thought to be the condition most commonly treated with the use of nonprescription drugs. Over-the-counter (OTC) analgesics such as nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen (APAP) are widely used for the self-treatment of a variety of acute painful conditions, e.g., headache, dental pain, dysmenorrhea, minor pain of arthritis, backache, muscular pain, and for fever. Traditional NSAIDs reduce pain and inflammation by reducing the synthesis of proinflammatory prostaglandins via inhibition of the enzyme cyclooxygenase-2 (COX-2), and also inhibit gastroprotective prostaglandins via inhibition of COX-1. The mechanism of action of APAP involves weak inhibition of COX-1 and COX-2 without anti-inflammatory activity. Based on the variable efficacy and safety profiles of OTC analgesics, and the emerging science, there is a need to improve the ability of healthcare professionals (including PCPs, PAs, NPs, pharmacists, etc.) to counsel patients on the appropriate selection and use of OTC analgesics, based on an accurate evaluation of their benefit/risk profiles, an understanding of different mechanisms of action, and individual patient profiles.
Method of Participation
Participants should first read the objectives and other introductory CME/CE information and then proceed to the educational activity. To receive credit for this activity, participants must complete the post-test with a passing score of 80% and then complete the evaluation. Credit is provided through December 15, 2019. No credit will be given after this date. There is no fee to participate in this activity.
In the event you have questions about this activity or are unable to retrieve the certificate, please email email@example.com and a certificate will be emailed within 2 weeks.
- Computer, tablet, or smartphone with internet access
- HTML5 compatible browser or Adobe Flash Player
In support of improving patient care, Dannemiller is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Dannemiller designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians Assistants may claim a maximum of 0.50 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
Dannemiller designates this educational activity for a maximum 0.50 contact hours.
Dannemiller is accredited by the American Association of Nurse Practitioners as an approved as a provider of nurse practitioner continuing education. Provider Number: 090419. This program is accredited for 0.50 contact hour(s) which includes 0.50 hours of pharmacology.
Dannemiller has assigned 0.50 contact hours (0.50 CEUs) of continuing pharmacy education credit to this activity. ACPE program number JA0002448-0000-19-001-H01-P.
Paul J. Christo, M.D., M.B.A.
Department of Anesthesiology and Critical Care Medicine
Division of Pain Medicine
The Johns Hopkins University School of Medicine
Ameet Nagpal, MD, MS, MEd
Clinical Assistant Professor, Department of Anesthesiology
Blaine Carmichael, RN, MPAS, PA-C, DFAAPA
Melissa Marie Gabel-Alvarado, RN, FNP-BC
Federico Roman Ng, MD, JD, RPh
In accordance with the Accreditation Council for Continuing Medical Education (ACCME), Dannemiller requires that any person who is in a position to control the content of a CME activity must disclose all relevant financial relationships they have with a commercial interest.
The following faculty have financial disclosed that they have the following relationships with commercial interests:
- Paul Christo, MD, MBA: Advisory/Medical Board – GlaxoSmithKline
The following faculty stated they have no relevant financial disclosure:
- Ameet Nagpal, MD, MS, MEd
- Blaine Carmichael, RN, MPAS, PA-C, DFAAPA
- Melissa Marie Gabel-Alvarado, RN, FNP-BC
- Federico Roman Ng, MD, JD, RPh
Jennifer Hodge, Dannemiller Project Manager and Scott Courtney, Audio Video, have no financial relationships with commercial interests.
To resolve identified/potential conflicts of interest, the educational content was fully reviewed by a member of the Dannemiller Clinical Content Review Committee who has nothing to disclose. The resulting certified activity was found to provide educational content that is current, evidence based and commercially balanced.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Dannemiller. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.